[CAS NO. 2999763-09-4] VT02956
PRODUCTS SPECIFICATIONS [2999763-09-4]
DESCRIPTION [2999763-09-4]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 373.45 |
| Molecular Formula | C22H23N5O |
| SMILES | NCC1CCN(CC1)C2=NC(C3=CC=NC=C3)=NC4=C2C=CC=C4C#CCO |
Summary
IC50 & Target
IC50: 0.76 nM for LATS1, 0.52 nM for LATS2 [1]
In Vitro
VT02956 (2 μM, 0-30 min) reduces YAP/TAZ phosphorylation in HEK293A cells and 4T1 cells
[1]
.
VT02956 (2 μM, 2 days) reduces ERα and its target genes TFF1 and GREB1 in breast tumor organoids BTO-02
[1]
.
VT02956 (2 μM, 4 days) inhibits the proliferation of ER+ breast cancer cells, such as MCF-7 and T47D cells
[1]
.
VT02956 (2 μM, 7 days) dramatically reduces MCF-7 growth when combined with Palbociclib (HY-50767) (0.1 and 0.3 μM)
[1]
.
VT02956 (2 μM, 9 days) results in a much more drastic reduction in colony formation of MCF-7 cells when combined with Palbociclib (HY-50767) (0.1 μM)
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | MCF-7 and T47D cells |
| Concentration: | 2 μM |
| Incubation Time: | 4 days |
| Result: | Inhibited the proliferation of ER+ breast cancer cells by targeting the LATS-YAP/TAZ-ERα. |
Western Blot Analysis [1]
| Cell Line: | HEK293A cells and 4T1 cells |
| Concentration: | 2 μM |
| Incubation Time: | 0-30 min |
| Result: | Inhibited YAP/TAZ phosphorylation with IC 50 s of 0.16 μM and 0.43 μM respectively. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.